




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁵ : C07D 401/06, 231/12, 231/18, A61K 31/415, 31/47 | A1 | (11) International Publication Number: WO 94/13661 (43) International Publication Date: 23 June 1994 (23.06.94) |
| (21) International Application Number: PCT/US93/09170 (22) International Filing Date: 30 September 1993 (30.09.93) (30) Priority Data: 07/992,228 17 December 1992 (17.12.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/992,228 (CIP) Filed on 17 December 1992 (17.12.92) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BRIGHT, Gene, M. [US/US]; 329 Tyler Avenue, Groton, CT 06340 (US). WELCH, Willard, M., Jr. [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US). (74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US). | | (81) Designated States: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> |
| (54) Title: SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS | | |
| (57) Abstract <p>The compounds of formula (I), wherein A, R₁, R₃, Z and Y are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.</p> <div style="text-align: right;">  <p>(I)</p> </div> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

-1-


SUBSTITUTED PYRAZOLES AS CRF ANTAGONISTS

5

This invention relates to substituted pyrazoles, pharmaceutical compositions containing them, and their use in the treatment of stress-related and other diseases. The compounds have corticotropin-releasing factor (CRF) antagonist activity.

CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is set out in the literature, e.g. as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M.J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are considered effective in the treatment of a wide range of diseases including stress-related illnesses, such as stress-induced depression, anxiety, and headache; abdominal bowel syndrome; inflammatory diseases; immune suppression; human immunodeficiency virus (HIV) infections; Alzheimer's disease; gastrointestinal diseases; anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction, and fertility problems.

The present invention relates to a compound of the formula



30 and the pharmaceutically acceptable acid addition salts thereof, wherein

A is CH₂;

R₁ is hydrogen; linear or branched C₁-C₆ alkyl; C₃-C₆ alkyl containing one or two non-adjacent double bonds; hydroxy; O(C₁-C₆ alkyl); SH; S(C₁-C₆ alkyl); C₃-C₆ cycloalkyl; morpholinyl, piperidinyl or aryl which aryl may be substituted by one to three of fluoro, chloro, bromo, trifluoromethyl, hydroxy, O(C₁-C₆ alkyl), SH, S(C₁-C₆ alkyl), amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, or one of iodo, nitro or cyano, said aryl being

-2-


selected from the group consisting of phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, and
 5 thiazolidinyl;

R_3 is linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl wherein the double bond is not adjacent to X_1 when X_1 is a heteroatom, or C_3 - C_7 cycloalkyl $(CH_2)_n$ wherein n is 0 to 4, or $(CH_2)_q Q_1 R_{19}$ wherein q is 0, 1 or 2, Q_1 is O, S, NH, $N(C_1$ - C_8 alkyl), or a covalent bond when X_1 is not a covalent bond, and R_{19} is hydrogen, linear C_1 - C_8 alkyl,
 10 branched C_3 - C_8 , C_3 - C_8 alkenyl, C_3 - C_8 cycloalkyl or C_3 - C_8 cycloalkyl (CH_2) ;

X_1 is a covalent bond, CH_2 , O, S, or NR, wherein R is hydrogen or linear C_1 - C_8 alkyl or branched C_3 - C_8 alkyl;

Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl,
 15 azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo, or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl; and

20 Z is
 (a)



30 wherein the B ring is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, thienyl, or indolyl, each of which may be substituted by methyl, methoxy, trifluoromethyl, fluoro, chloro, bromo or iodo; or a

-3-

saturated 5- or 6-membered carbocyclic ring or a partially unsaturated ring having one or two double bonds;

R_4 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, fluoro, chloro, bromo, iodo, or trifluoromethyl;

5 R_5 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, or $(CH_2)_o$ - X_2 -(CH_2) $_r$ - Q_2 - R_6 ;

X_2 and Q_2 are each independently O, S, NH, N(C_1 - C_6 alkyl), or one of X_2 and Q_2 may be a covalent bond;

R_6 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl or C_3 - C_8 alkenyl;

10 m is 0 or 1;


o is 1 or 2;

p is 1 or 2; and

r is 0, 1 or 2

(b)

15



20

wherein R_4 and R_6 are as defined above, and t and u are each independently 1 or 2;


(c) $-NR_7R_8$ wherein R_7 and R_8 are each independently hydrogen, C_1 - C_6 linear alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, $(CH_2)_vCH_2OH$, $(CH_2)_vNR_9R_{10}$, wherein v is 0 to 3, and R_9 and R_{10} are each independently hydrogen, or linear C_1 - C_6 alkyl; $(C_3$ - C_{12} cycloalkyl) $(CH_2)_n$, $(C_6$ - C_{10} bicycloalkyl) $(CH_2)_n$, benzofused C_3 - C_8 cycloalkyl, C_1 - C_6 hydroxyalkyl, phenyl $(CH_2)_n$, each of which may be substituted by one or two of hydroxy, fluoro, chloro, bromo, C_1 - C_6 alkyl, or C_1 - C_6 alkoxy; or R_7 and R_8 may be taken together with the nitrogen to form a saturated or partially unsaturated 5- to 7-membered ring which may contain one of O, S, NH or N(C_1 - C_6 alkyl) and which may be substituted by C_1 - C_6 alkyl, hydroxy or phenyl wherein any double bond(s) are not adjacent to any heteroatoms; and n is 0 to 4;

25

30


-4-

(d)




wherein B, R_4 and R_5 are as defined above, w, x, y and z are each independently 1 or 2, and W is $(CH_2)_q$ wherein q is as defined above, $N(C_1-C_6 \text{ alkyl})$, or oxygen;

(e)



wherein B, W, R_4 , m and p are as defined above;

(f)




wherein B and R_4 are as defined above;

(g) $O(CH_2)_v R_{11}$

-5-

wherein v is 0 to 3 and R_{11} is linear C_1-C_6 alkyl, branched C_3-C_8 alkyl, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, or thienyl, each of which may be substituted by one or two of any one of fluoro, chloro, bromo, methyl, or trifluoromethyl;

(h)




15

wherein A is as defined above and is linked to position 1 or 2 while R_{14} is attached to position 2 or 1, respectively; F, G, H, I, J and K are independently C or N , provided that not more than three of H, I, J and K are N with not more than two adjacent nitrogens; R_{12} and R_{13} each independently are hydrogen, linear C_1-C_6 alkyl, branched C_3-C_8 alkyl, C_3-C_8 alkenyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, thiol, C_1-C_{12} alkoxy, C_1-C_{12} thioalkanyl, or C_3-C_{12} alkenoxy or C_3-C_{12} thioalkenyl wherein the double bond is not adjacent to the oxygen or sulfur; and R_{14} is hydroxy, C_1-C_{12} alkoxy, C_3-C_{12} alkenoxy wherein the double bond is not adjacent to the oxygen, or $-X_2-(CH_2)_r-Q_2-R_6$ wherein X_2, r, Q_2 and R_6 are as defined above in paragraph (a) except that Q_2 is not sulfur, or R_{14} is $NR_{15}R_{16}$ wherein R_{15} and R_{16} are each independently hydrogen, linear C_1-C_6 alkyl, branched C_3-C_8 alkyl, C_3-C_8 alkenyl wherein the double bond is not adjacent to the nitrogen, or C_3-C_7 cycloalkyl- $(CH_2)_n$ wherein n is as defined above, or R_{15} and R_{16} together with the nitrogen form a saturated five or six membered ring optionally condensed with benzo; or

30

-6-


(i)



5

wherein D, E, F and G are independently C or N, provided that not more than two of D, E, F and G are N, R_{12} and R_{14} are as defined above, A, defined above, is linked to a carbon in formula VIII, and R_{14} is linked to a carbon located adjacent to the carbon
10 to which A is linked.

Preferred compounds of formula I are those wherein Z is 1,2,3,4-tetrahydroquinolin-2-yl substituted by R_5 which is $(CH_2)_6-X_2-(CH_2)_7-Q_2-R_6$, or more preferably R_5 is $(CH_2)_kOH$ wherein k is 1 to 4, or $CH_2OCH_2CH_2OR_6$. Other preferred compounds are those wherein Z is 1,2,3,4-tetrahydroisoquinolin-2-yl, wherein R_5 is
15 substituted at position 3, and the absolute configuration at the 3-position is S or R or R,S. Further preferred compounds are those wherein Z is of the formula



20

with the absolute configuration at position 3 determined by its derivation from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline, wherein R_{19} is methyl, ethyl, isopropyl, cyclopropylmethylene, or 2-hydroxyethyl, and, more preferably, wherein in addition XR_3 is ethyl or methylthio, Y is 2,6-dichloro-4-trifluoromethylphenyl, 2,4,6-trichlorophenyl,
25 2,4,6-trimethylphenyl, 2,6-dimethyl-4-bromophenyl, or 2,6-dibromo-4-fluorophenyl, and R_1 is methyl or ethyl.

More specific compounds of formula I are those wherein Z is as defined in (h), and, more specifically, A is linked to position 1, and R_{14} is at position 2 and is $X_2-(CH_2)_7-Q_2-R_6$; or A is linked to position 1, F, G, H, I, J, and K are each carbon, and R_{14}
30 is 2-methoxy, 2-ethoxy, 2-isopropoxy, or 2-cyclopropylmethoxy; or


A is linked to position 1, K is nitrogen, F, G, H, I and J are each carbon, and R_{14} is at position 2 and is $X_2-(CH_2)_7-Q_2-R_6$; or

-7-

A is linked to position 1, K is nitrogen, F, G, H, I, and J are each carbon, and R_{14} is at position 2 and is methoxy, ethoxy, isopropoxy, or cyclopropylmethoxy, $\text{HOCH}_2\text{CH}_2\text{O}-$, or $\text{CH}_3\text{OCH}_2\text{CH}_2\text{O}-$; or


A is at position 1 and R_{14} is at position 2 and is ethoxy, isopropoxy, cyclopropylmethoxy, $\text{HOCH}_2\text{CH}_2\text{O}$ or $\text{CH}_3\text{OCH}_2\text{CH}_2\text{O}-$.

More specific compounds of formula I include those wherein Z is



wherein K is C or N and R_{20} is methyl, ethyl, isopropyl, cyclopropylmethylene, methoxyethylene, hydroxyethylene, and, more specifically, in addition X_1R_3 is ethyl or methylthio, Y is 2,6-dichloro-4-trifluoromethylphenyl, 2,4,6-trichlorophenyl or 2,6-dibromo-4-fluorophenyl, and R_1 and R_2 are each methyl or ethyl.

Other more specific compounds are those of formula I wherein Z is as defined in (a), B is phenyl, p and m are each 1, and R_6 is CH_2OCH_3 or $\text{CH}_2\text{OCH}_2\text{CH}_2\text{OH}$; and those wherein Z is



More specific compounds of formula I of the invention include those wherein Y is phenyl substituted by three substituents one each at positions 2, 4 and 6, e.g. 2,4,6-trichlorophenyl, 2,6-dimethyl-4-bromophenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dibromo-4-fluorophenyl or 2,4,6-trimethylphenyl. Other more specific compounds of formula I include those wherein X_1R_3 is ethyl or methylthio, those wherein R_1 is (C_1-C_8) alkyl, and those wherein Z is NR_7R_8 and R_7 is phenyl or phenyl substituted by one of

fluoro, chloro, nitro, methyl or methoxy and R_8 is as defined above, preferably, $(CH_2)_3OH$, CH_2CH_2OH or methyl.

Specific, preferred compounds of formula I include 3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; (3R)-3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; 3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; {2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol; {2-[5-methyl-3-methylsulfanyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol; 2-{1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl}-naphthalene-2-yloxy}-ethanol; 2-{8-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-quinolin-7-yloxy}-ethanol; 2-[3,5-diethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline; or 1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-4-(2-methoxynaphthalen-1-ylmethyl)-1H-pyrazole; 2-{2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-ylmethoxy}-ethanol; 2-{1-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol; 2-[1-(4-bromo-2,6-dimethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline; 2-[1-(4-bromo-2,6-dimethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-ethoxymethyl-1,2,3,4-tetrahydroisoquinoline; and 2-{2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-ylmethoxy}-ethanol.

Specific, most preferred compounds of formula I include 2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline, 2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-3-ethoxymethyl-1,2,3,4-tetrahydroisoquinoline, 2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline, and 2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-3-ethoxymethyl-1,2,3,4-tetrahydroisoquinoline.

The invention includes a compound of the formula IA (not shown) and the pharmaceutically acceptable acid addition salt thereof. The compounds of the formula


-9-

IA are identical to those of formula I except that A is $\text{CH}(\text{C}_1\text{-C}_8 \text{ alkyl})$, $\text{C}(\text{C}_1\text{-C}_8 \text{ alkyl})_2$, $\text{C}(\text{C}_1\text{-C}_8 \text{ alkyl})(\text{C}_3\text{-C}_8 \text{ alkenyl})_2$, or $\text{CH}(\text{CH}_2)_n(\text{C}_3\text{-C}_8 \text{ alkenyl})$ wherein n is 0 to 4.

The invention also relates to a pharmaceutical composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) stress and anxiety related disorders, including stress-induced depression and headache, abdominal bowel syndrome, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal disease, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises a compound of the formula I or IA as defined above in an amount effective in the treatment of said illnesses or disorders, and a pharmaceutically acceptable carrier. Preferred compositions of the invention are those containing preferred compounds of formula I as described above.

The invention further relates to a method for the treatment of illnesses induced or facilitated by corticotropin releasing factor by administering to a subject in need of such treatment a compound of formula I or IA as defined above in an amount effective in such treatment, and a method for the treatment of stress and anxiety related disorders, including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, particularly depression, by administering to a subject in need of such treatment a compound of formula I or IA as defined above in an amount effective in such treatment. Preferred methods of the invention are those administering a preferred compound of the formula I as described above.

The invention also relates to an intermediate compound of the formula



30

-10-

wherein A is CH₂, R₃ is linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl wherein the double bond is not adjacent to the N or X₁ when X₁ is oxygen or sulfur, C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or (CH₂)_qQ₁R₆ wherein q is 0, 1 or 2, Q₁ is O, S, NH, N(C₁-C₆ alkyl) or a covalent bond, and R₆ is hydrogen, linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl, C₃-C₈ cycloalkyl, or C₃-C₈ cycloalkyl (CH₂)_n wherein n is 0 to 4, with the proviso that when q is 1, then X₁ and Q₁ can not both be a heteroatom;

X₁ is a covalent bond, CH₂NR, wherein R is hydrogen or linear C₁-C₆ alkyl, O, or S;


Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo, or methyl, or one of trifluoromethyl, provided that Y is not unsubstituted phenyl, and

L is chloro, bromo, iodo, hydroxy, O(C=O)(C₁-C₆ alkyl), OSO₂(C₁-C₆ alkyl), OSO₂aryl wherein said aryl is phenyl which may be substituted by one to three of fluoro, chloro, bromo, hydroxy, O(C₁-C₆ alkyl), SH, S(C₁-C₆ alkyl), amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, or one of iodo, nitro or cyano.

Whenever reference herein is made to the groups (CH₂)_qQ₁R₆ and (CH₂)_o-X₂-(CH₂)_rQ₂R₆, then X₁ and Q₁, and X₂ and Q₂, respectively, are not both a heteroatom when q or r, respectively, is 1.

Whenever R₁ or Y is a heterocyclic group, the attachment of the group is through a carbon atom.

The compounds of formula I may be prepared by reaction of a compound of the formula




-11-

wherein R_1 and Y are as defined above with reference to formula I, with a compound of the formula ZH wherein Z is as defined above.

This reaction generally proceeds at temperatures ranging from about 0° to 85°C , usually at room temperature. The reaction is conveniently carried out in a solvent which is inert under the reaction conditions, e.g. acetonitrile. The compound of formula IX is first reacted with an activated sulfonic acid such as methylsulfonyl chloride in the presence of an acid neutralizing agent such as triethylamine in an inert solvent such as methylene chloride at about -10° to about 50°C , before reaction with ZH .

The compounds of formula IX may be prepared by reacting a compound of the formula



20 wherein R_1 , X_1 and Y are as defined with reference to formula I and R_{17} is $\text{C}_1\text{-C}_8$ alkyl, with a reducing agent such as diisobutylaluminum hydride at temperatures of about -10° to about 80°C , in a reaction-inert solvent such as tetrahydrofuran or ether.

The compounds of formula X may be prepared by reaction of a compound of the formula




30 with a compound of the formula $Y\text{-NHNH}_2$, wherein X_1 , R_1 , R_3 and Y are as defined with reference to formula I, M is O or S , R_{17} is as defined above with reference to formula X, and R_{18} is $\text{C}_1\text{-C}_8$ alkyl. The reaction is usually carried out in a solvent, such as a $\text{C}_1\text{-C}_8$ alcohol, at least 50 to 150°C , conveniently the reflux temperature of the reaction

-12-

mixture. The wavy line \sim in formula XI indicates that either isomer of this compound is included, in accordance with accepted conventions for indicating stereoisomers.

The compounds of formula XI above may be prepared by reacting an appropriate beta-ketoester with a base such as sodium hydride in the presence of carbon disulfide in an appropriate solvent or mixture of solvents such as dimethylsulfoxide or dimethylformamide at a temperature of about -10° to about 40°C followed by quenching of the resulting dianion with an appropriate alkylating agent such as methyl iodide resulting in a 3,3-bismethylthioacrylate derivative XI wherein R_{18} is R_3 is CH_3 and M is X_1 is S. Reaction of compounds of the formula XI wherein M is X_1 is S and R_3 is R_{18} is $\text{C}_1\text{-C}_6$ alkyl with alcohols $R_3\text{OH}$ in the presence of base then results in the preparation of the corresponding compounds XI wherein R_{18} is R_3 and M is X_1 is O.

Reaction of an appropriate beta-ketoester with an ortho ester of one of the following formulas:



wherein n, R_{19} , Q_1 , q, and X_1 are as defined with reference to formula I, in an appropriate solvent such as ethyl acetate at temperatures of about 0° to about 100°C results in compounds of the formula XI wherein R_{18} is $\text{C}_1\text{-C}_6$ alkyl, M is O, X_1 is CH_2 or a covalent bond, and R_3 is, respectively, $(\text{C}_1\text{-C}_6 \text{ alkyl})\text{-(CH}_2\text{)}_n$; $(\text{C}_2\text{-C}_6 \text{ alkenyl})\text{-(CH}_2\text{)}_n$; and $R_{19}Q_1(\text{CH}_2)_q\text{-X}_1\text{-(CH}_2\text{)}_n$, wherein n, q, R_{19} , Q_1 and X_1 are as defined above.

Reaction of the compounds of the formula XI wherein M is X_1 is S and R_3 is R_{18} is $\text{C}_1\text{-C}_6$ alkyl with amines such as RNH_2 or RR_3NH in an appropriate solvent such as ethanol at temperatures of about 0° to about 100°C results in compounds of the formula XI in which either or both of $R_{18}\text{-M}$ and $X_1\text{-R}_3$ are each RNH or NRR_3 , wherein R is as defined with reference to formula I and R_3 is linear alkyl, branched $\text{C}_3\text{-C}_8$ alkyl, or $\text{C}_3\text{-C}_8$ alkenyl wherein the double bond is not adjacent to the nitrogen.

The compounds of formula I wherein Z is as defined above in paragraphs (a), (h) or (i) wherein R_5 or R_{14} is $X_2(\text{CH}_2)_2Q_2R_6$, wherein Q_2 is oxygen, and X_2 , r, and R_6 are as previously defined except that R_6 is not hydrogen, may be prepared by alkylation of the corresponding compound wherein R_5 or R_{14} are $(\text{CH}_2)_6\text{-X}_2\text{-(CH}_2\text{)}_2\text{-Q}_2\text{-R}_6$ and $\text{-X}_2\text{-(CH}_2\text{)}_2\text{Q}_2\text{R}_6$, respectively, wherein R_6 is hydrogen and Q_2 is oxygen. In these cases

-13-


wherein R_5 and R_{14} have a terminal hydroxy group, the hydroxy is first reacted with a strong base such as an alkali metal hydride, e.g. lithium, sodium or potassium hydride, in a solvent such as dimethylformamide at about 50° to 100°C.

The resulting alkali metal alkoxide is then reacted with an alkyl or aryl sulfonyl ester of the formula $HO(CH_2)_qQ_2R_6$ wherein R_6 is as defined in paragraph (a) except hydrogen. This reaction is carried out in the presence of a solvent such as methylene chloride or toluene at about 50° to 100°C. The above sulfonyl esters may be prepared by the same method as described above for the activation of the compound of formula IX.

The above alkali metal hydride may be replaced by other strong bases including organometallic bases such as *n*-butyl lithium or amine anion bases such as lithium diisopropylamide. In such case, the metal alkoxide formation reaction may be carried out in tetrahydrofuran at temperatures of about -5° to about 65°C.

The same alkylation may be used to prepare compounds of the formula I wherein X_1 is oxygen and R_3 is $(CH_2)_qQ_1R_{19}$ wherein q , Q_1 and R_{19} are as defined above with reference to formula I except that R_{19} is not hydroxy, from the corresponding compounds wherein X_1R_3 is hydroxy.

The compounds of the formula IX wherein R_3 is $(CH_2)_qQ_1R_6$ wherein q is as defined with reference to formula I, Q_1 is O and R_6 is methyl, react with ZH, as defined above, to form compounds of the formula




These compounds may be reacted with a demethylating agent to form the corresponding compound wherein R_6 is hydrogen. A suitable demethylating agent is boron tribromide in combination with sodium iodide and 15-crown-5, as described in the prior art.

The compounds of formula IA wherein A is $\text{CH}(\text{C}_1\text{-C}_8 \text{ alkyl})$, or $\text{CH}(\text{CH}_2)_n(\text{C}_3\text{-C}_8 \text{ alkenyl})$ wherein n is 0 to 4 (having formula IB, not shown) may be prepared from the

-14-

compounds of formula IX by reaction with a Grignard reagent of the formula $R_{19}MgHal$ wherein R_{19} is C_1 - C_6 alkyl, or $(CH_2)_n(C_3$ - C_8 alkenyl) wherein n is 0 to 4, in a conventional manner, e.g. in diethyl ether or tetrahydrofuran solvent at about -78° to $50^\circ C$, to form a ketone of the formula

5




10

The ketone XVI may be converted to the corresponding enamine by reaction with a compound of the formula ZH wherein Z is (a) to (d) as defined above under standard acid catalyzed dehydrogenation conditions. The enamine may be converted into the compounds of formula IA wherein A is CHR_{19} by hydrogenation with hydrogen under pressure in the presence of a noble metal catalyst or reduction with a hydride such as sodium or lithium cyanoborohydride in diethylether or tetrahydrofuran (THF).

Alternatively, the compounds of formula IB may be prepared from compounds IX by reaction with ZH wherein Z is (a) to (d) as defined above in the presence of a hydride reducing agent such as sodium or lithium cyanoborohydride.

The compounds of formula IA wherein A is $C(C_1$ - C_6 alkyl) $_2$, or $C(C_1$ - C_6 alkyl)(C_3 - C_8 alkenyl) may be prepared from the compound of formula IX by reaction with concentrated hydrochloric acid under reflux to form a compound of the formula

25



The compound XVII may be brominated, e.g. with pyridinium bromide in THF, to form the corresponding 4-bromide of formula XVIII (not shown) which may be 4-metalated in situ, such as with *t*-butyl lithium in diethyl ether at $-78^\circ C$, and then treated in situ with

30


-15-

an iminium compound of the formula
$$\begin{array}{c} \text{Z}^{(+)} = \text{C} \begin{array}{l} \nearrow \text{R}_{19} \\ \searrow \text{R}_{20} \end{array} \text{X}^{(-)} \end{array}$$
 wherein R_{19} is as defined

above, R_{20} is R_{19} , Z is (a) to (d) as defined above, and X is halogen.


The compounds of formula IA wherein A is CHR_{19} wherein R_{19} is as defined above, Z is (h) or (i) as defined above and R^{14} does not have acidic hydrogens, such as hydroxyls, may be prepared from compounds of the formula I wherein Z is (h) or (i) and the other substituents are as defined above with reference to formula I by treatment with a strong base such as t-butyl lithium in ether or THF and subsequent alkylation in the same solvent with a halide of the formula R_{19}X wherein R_{19} and X are as defined above.

When the compounds of the invention contain a chiral center, it is understood that the invention includes the racemic mixture and the individual enantiomers of such compounds. For instance, the compounds of the invention wherein Z is 1,2,3,4-tetrahydroisoquinolinyl have a chiral center when Z is substituted at position 3 by R_5 , wherein R_5 is as defined with reference to formula I except hydrogen, as follows:



wherein the chiral center is indicated by an asterisk.

Preferred compounds of the invention of formula I include those derived from the dextrorotatory (+) enantiomer of the intermediate compound ZH of the formula



wherein R_5 is hydroxymethyl or (C_1 - C_6 alkoxy) methyl.

The acid addition salts are prepared in a conventional manner by treating a solution or suspension of the free base of formula I or IA with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization

-16-

techniques are employed in isolating the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

5 The novel compounds of the invention of formula I or IA may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I or IA and the
10 pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium
15 carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for
20 tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such
25 as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions of the novel compound of formula I in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular
30 aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

-17-

Additionally, it is possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes, and ointments, in accordance with standard pharmaceutical practice.

5 The effective dosage for the compound of formula I or IA depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated. The daily dosage will generally range from about 0.1 to 50 mg/kg of the body weight of the patient to be treated. For the treatment of inflammatory diseases
10 about 0.1 to about 100 mg/kg will be needed in general, for gastrointestinal diseases about 0.1 to about 50 mg/kg, as well as for anorexia nervosa, hemorrhagic stress, treatment of drug and alcohol withdrawal symptoms and treatment of fertility problems. The daily dosage may be given in a single dose or up to three divided doses.

 The methods for testing the compounds of formula I or IA for their CRF
15 antagonist activity are as described in Endocrinology, 116, 1653-1659 (1985) and Peptides 10, 179-188 (1989) which determine the binding activity of a test compound to a CRF receptor. The binding activity for the compounds of formula I generally ranges from about 0.2 nanomolar to about 10 micromolar.

 The following Examples illustrate the invention. The designation Et means ethyl.

20

EXAMPLE I

A. Ethyl 3,3-bismethylthio-2-acetylacrylate.

 A solution of 6.50 g (50.0 mmol) of ethyl acetoacetate and 4.18 g (3.30 mL, 55.0 mmol) of carbon disulfide in 60 mL of dry dimethylsulfoxide in a flame-dried 300 mL flask was treated portionwise at 16 - 18°C with 2.64 g (110 mmol) of oil-free sodium
25 hydride. An additional 100 mL of dimethylsulfoxide was eventually added to facilitate stirring. After the addition was complete, the deep red solution was stirred for 75 minutes and then was quenched with 15.62 g (6.85 mL, 110 mmol) of methyl iodide. The reaction mixture was stirred overnight at room temperature. The solution was poured into water and extracted with ether. The extracts were washed with water, dried
30 and evaporated to give a red oil which was used for subsequent reactions without further purification. ¹H-NMR (CDCl₃) δ 1.24 (3H, t, J=7), 2.28 (3H, s), 2.37 (6H, s), 4.21 (2H, q, J=7).

-18-

B. 4-Ethoxycarbonyl-5-methyl-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole.

A mixture of 1.22 g (5.23 mmol) of ethyl 3,3-bismethylthio-2-acrylate and 1.11 g (5.23 mmol) of 2,4,6-trichlorophenylhydrazine in 12 mL of ethanol was heated at reflux for 2 hours. The cooled reaction mixture was then poured into cold water and the product was extracted into ether. The ethereal extracts were dried and evaporated and the residues were chromatographed on silica gel using 6:1 hexane/ethyl acetate as eluent to give 1.12 g (56%) of the desired product as a crystalline solid, m.p. 95-98°C. ¹H-NMR (CDCl₃) δ 1.38 (3H, t, J=7), 2.30 (3H, s), 2.49 (3H, s.), 4.31 (2H, q, J=7), 7.47 m(2H, s).

10 C. 2-(5-Methyl-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazol-4-yl)methyl-1,2,3,4-tetrahydroisoquinoline.

A solution of 0.340 g (0.89 mmol) of 4-ethoxycarbonyl-5-methyl-3-methylthio-1-(2,3,6-trichlorophenyl)pyrazole in 10 mL of tetrahydrofuran was cooled to 0°C in an ice bath under dry nitrogen and then 2.37 mL of a 1.5 M solution of diisobutylaluminum hydride in toluene (3.56 mmol) was added. The reaction mixture was allowed to warm to room temperature and stir for 2 hours. Then water was added cautiously and the product was extracted into ether which was dried and evaporated to give the product which was used for the subsequent reaction without further purification. ¹H-NMR (CDCl₃) δ 2.07 (3H, s), 2.53 (3H, s), 4.56 (2H, d, J=7), 7.45 (2H, s).

20 The above product was dissolved in 10 mL of methylene chloride and 0.62 mL (0.45 g, 4.45 mmol) of triethylamine at 0 - 5°C and treated with 0.21 mL (0.31 g, 2.67 mmol) of methanesulfonyl chloride. After 1 hour at room temperature, the reaction mixture was poured into water and was extracted with ethyl acetate. The solution of product was dried with brine and magnesium sulfate and the solvent was evaporated to give the intermediate mesylate which was used in the subsequent step without further purification.


30 The product of the above reaction (0.98 mmol) was dissolved in 10 mL of acetonitrile and treated with 0.45 mL (0.475 g, 3.57 mmol) of 1,2,3,4-tetrahydroisoquinoline. The solution darkened and then lightened over a period of a few minutes and was then stirred overnight at room temperature. Solids which had formed were filtered off and discarded and the filtrate was concentrated and chromatographed on silica gel using 4:1 hexane/ethyl acetate as eluent to give the product free base. This material was dissolved in ether and treated with a solution of

-19-

hydrogen chloride (gas) in ether to give the product hydrochloride, m.p. 205-207°C (53% over the three reactions). Anal. Calcd for $C_{21}H_{20}N_3SCl_3$: C, 51.55; H, 4.33; N, 8.59. Found, C, 51.01; H, 4.69; N, 8.40.

EXAMPLE 2

5 The following compounds were prepared by the process of Example 1.



| | R_1 | R_2 | R_6 | R_7 | Physical data (m.p. in °C) |
|----|-----------------------------------|-----------------|------------------|------------------|--|
| | CH ₃ | Cl | H | H | m.p. 205-207 |
| 20 | CH(CH ₃) ₂ | Cl | H | H | m.p. 209-210 |
| | CH(CH ₃) ₂ | Cl | OCH ₃ | OCH ₃ | m.p. 140-142 |
| 25 | phenyl | CF ₃ | H | H | ¹ H-NMR(CDCl ₃) δ 2.59 (s, 3H), 2.74 (2H, t, J=7), 2.89 (2H, t, J=7), 3.54 (2H, s), 3.64 (2H, s), 6.98-7.01 (1H, m), 7.07-7.15 (3H, m), 7.25-7.32 (3H, m), 7.37-7.42 (2H, m), 7.60 (2H, m). |

EXAMPLE 3

30 A. 4-Methoxycarbonyl-3,5-heptanedione.

A solution of 6.5 g (50 mmol) of methyl propionyl acetate in 100 mL of ether was treated with 1.19 g (50 mmol) of sodium hydride and the mixture was stirred for 2

-20-

hours. The mixture was then cooled to 5 °C and 6.93 g (6.51 mL, 75 mmol) of propionyl chloride was added dropwise over 5 minutes. The reaction mixture was stirred overnight at room temperature and then poured into cold water. This mixture was acidified with sulfuric acid and the product was extracted into ether, washed with
5 water and dried. Evaporation gave the desired product, sufficiently pure for use in the following reaction, in 88% yield. ¹H-NMR (CDCl₃) δ 1.08 (6H, t, J=7), 2.58 (4H, q, J=7), 3.66 (1H, s), 3.74 (3H, s).

B. Methyl 1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethylpyrazole-4-carboxylate.

10 A solution of 7.5 g (40 mmol) of the compound of step A and 11.85 g (48 mmol) of 2,6-dichloro-4-trifluoromethylphenyl hydrazine in 50 mL of ethanol was heated at reflux for 8 hours. The ethanol was removed by evaporation and the residues were partitioned between ethyl acetate and dilute hydrogen chloride. The organic extracts were dried and evaporated to give the desired product in 43% yield as a maroon oil.
15 ¹H-NMR (CDCl₃) δ 1.08 (3H, t, J=7), 1.24 (3H, t, J=7), 2.22 (2H, q, J=7), 2.94 (2H, q, J=7), 3.86 (3H, s), 7.46 (2H, s).

C. [1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-yl]methanol.

A solution of 8 g (20 mmol) of the compound of step B in 50 mL of tetrahydrofuran (THF) was treated at °C with 44.1 mL of 1.5 M diisobutylaluminum
20 hydride in toluene solution over a period of 5 minutes. The reaction was stirred for 2 hours at °C and was then cautiously quenched with water. The product was extracted into ethyl acetate and dried and evaporated to give the title compound in 46% yield. ¹H-NMR (CDCl₃) δ 1.04 (3H, t, J=7), 1.26 (3H, t, J=7), 2.44 (2H, q, J=7), 2.70 (2H, q,
25 J=7), 4.54 (2H, s), 7.66 (2H, s).

D. 1-[3,5-Diethyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-pyrazol-4-ylmethyl]naphthalen-2-ol.

A solution of 303 mg (2.1 mmol) of 2-naphthol in 5 mL of dry ether was treated with 50 mg (2.1 mmol) of sodium hydride and the mixture was stirred for 15 minutes.
30 A solution of 368 mg (1.0 mmol) of the compound of step C in 5 mL of dry ether and 126 mg (0.174 mL, 1.22 mmol) of triethylamine was cooled to 0°C and treated with 114 mg (0.077 mL, 1.0 mmol) of methanesulfonyl chloride. Triethylamine hydrochloride was removed by filtration and the filtrate was added to the above suspension of sodium 2-

-21-

naphthoxide and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then partitioned between water and ether and the organic extracts were dried and evaporated to give the desired product in 29% yield. ¹H-NMR (CDCl₃) δ 1.00 (3H, t, J=7), 1.20 (3H, t, J=7), 2.44 (2H, q, J=7), 2.72 (2H, q, J=7), 4.58 (2H, s), 6.96 - 7.84 (8H, m).

E. 3,5-Diethyl-4-(2-methoxynaphthalen-1-ylmethyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-pyrazole.

A solution of 100 mg (0.20 mmol) of the compound at step D in 5 mL of dry THF was treated with 5 mg (0.20 mmol) of sodium hydride and stirred for 15 minutes. Then 85 mg (0.037 mL, 0.60 mmol) of methyl iodide was added and the mixture was stirred overnight at room temperature. The reaction mixture was quenched with water and the product was extracted into ethyl acetate, dried and evaporated. Flash column chromatography gave the desired product as a white solid, m.p. 96 - 98°C. ¹H-NMR (CDCl₃) δ 0.6 (3H, t, J=7), 1.04 (3H, t, J=7), 2.06 (2H, q, J=7), 2.51 (2H, q, J=7), 3.90 (3H, s), 4.14 (2H, s), 7.18 - 7.34 (3H, m), 7.58 (2H, s), 7.70 - 7.84 (3H, m).

EXAMPLE 4

8-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-quinolin-7-ol

By the general method of Example 3D, substituting 7-hydroxyisoquinoline for 2-naphthol, the title compound was prepared [45 mg of an oil, isolated after flash chromatography (silica gel, 40 micron mesh; elution with ethylacetate/hexane=1:4 in volume), from reaction utilizing 264 mg (0.75 mmol) of the compound of Example 3C as starting material. ¹H-NMR(CDCl₃): 0.83 (3H, t), 1.09 (3H, t), 2.37 (2H, q), 2.50 (2H, q), 4.64 (2H, s), 7.14 (1H, d), 7.30 (1H, dd), 7.64 (1H, d), 7.70 (2H, s).

EXAMPLE 5

A. 2-{1-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol tert-butyl-dimethylsilylether

To a tetrahydrofuran (1.0 ml) solution of the compound of Example 3D (150 mg, 0.30 mmol), sodium hydride (37 mg of 60% sodium hydride mineral oil dispersion; 22.2 mg, 0.93 mmol of sodium hydride) was added portionwise over several minutes; 1-iodo-2-(tert-butyldimethylsilyloxy)ethane (858 mg, 0.30 mmol) was added, and the reaction was stirred and heated at 45°C for 48 hours. An additional (858 mg, 0.30 mmol) portion of 1-iodo-2-(tert-butyldimethylsilyloxy)ethane was added; and the reaction was

-22-

then heated at 45°C for an additional 18 hours. The solvent was removed in vacuo, and the residue was extracted into ethyl acetate/water (100 ml of each). The separated aqueous layer was extracted twice with 30 ml portions of ethyl acetate. The combined organic extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to an oil (1.95 g). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethyl acetate/hexane=5:95 in volume) afforded the title compound (40 mg) as an oil. ¹H-NMR(CDCl₃): 0.10(6H, s), 0.60 (3H, t), 0.90 (9H, s), 1.10 (3H, t), 2.10 (2H, q), 2.56 (2H, q), 4.00 (2H, q), 4.20 (2H, q), 4.32 (2H, s), 7.25-7.38 (3H, m), 7.65 (2H, s), 7.73-7.87 (3H, m).

10 B. 2-{1-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-naphthalen-2-yloxy}-ethanol

A tetrahydrofuran (0.40 ml) solution of the compound of step A, (40 mg, 0.06 mmol) and tetrabutylammonium fluoride (123 μ l of a 1.00 M tetrahydrofuran (THF) solution, 0.123 mmol) was stirred at ambient temperature for 3 hours. The solvent was removed in vacuo, and the residue was extracted into ethyl acetate/water (60 ml of each). The separated organic phase was extracted twice with equal volume portions of water, dried over anhydrous sodium sulfate, and concentrated in vacuo to an oil (49 mg). Flash chromatography of the entire sample (silica gel, 40 micron mesh; elution with ethylacetate/hexane=3:7 in volume) afforded the title compound (24 mg) as an amorphous solid. ¹H-NMR(CDCl₃): 0.58(3H,t), 1.15 (3H, t), 1.99 (1H, broad), 2.07 (2H, q), 2.58 (2H, q), 3.99 (2H, m), 4.23 (2H, t), 4.32 (2H, s), 7.2-7.45 (3H, overlapping multiplets), 7.66 (2H, s), 7.80 (2H, dd), 7.91 (1H, d).

EXAMPLE 6

25 A. {2-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol

A solution of 368 mg (1.0 mmol) of [1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-yl]methanol in 10 mL of methylene chloride and 0.2 mL (2.5 mmol) of triethylamine was cooled to 0 - 5 °C. To this was added 0.92 mL (1.2 mmol) of methanesulfonyl chloride and the reaction mixture was stirred at 0 - 5 °C for 15 minutes. Then 1 mL of acetonitrile and 1 mL of dimethylformamide was added and the reaction mixture was heated at reflux overnight. The cooled reaction mixture was taken up with water and with ethyl acetate and the organic extracts were dried and evaporated to an orange oil which was purified by flash chromatography to give the

-23-

desired product in 45% yield. $^1\text{H-NMR}$ (CDCl_3) δ 0.86 (3H, t, $J=7$), 1.21 (3H, t, $J=7$), 2.28 (2H, q, $J=7$), 2.60 (2H, q, $J=7$), 2.92-3.04 (1H, m), 3.20-3.32 (1H, m), 3.50-3.90 (7H, m), 6.90-7.24 (4H, m), 7.68 (2H, s).


B. 2-[1-(2,6-Dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline

A solution of 200 mg (0.39 mmol) of the compound of step A in 5 mL of THF was treated with 10 mg (0.42 mmol) of sodium hydride and stirred for 30 minutes at room temperature. Then 0.1 mL (1.6 mmol) of methyl iodide was added and the reaction mixture was stirred at room temperature for 24 hours. The reaction was quenched with water and the product was extracted into ethyl acetate which was dried and evaporated. The crude product was flash chromatographed on silica gel to give the desired product in 26% yield as a colorless oil. $^1\text{H-NMR}$ (CDCl_3) δ 0.90 (3H, t, $J=7$), 1.20 (3H, t, $J=7$), 2.39 (2H, q, $J=7$), 2.65 (2H, q, $J=7$), 2.88-2.96 (1H, m), 3.16-3.20 (1H, m), 3.32 (3H, s), 3.55-3.78 (7H, m), 6.90-7.24 (4H, m), 7.65 (2H, s).

EXAMPLE 7

The following compounds were prepared according to the process of Example

6.



-24-

| | R | R ₁ | R ₂ | X | ¹ H-NMR | |
|----|------------|-----------------|-----------------|------------------|--------------------|--|
| 5 | Racemate | H | CH ₃ | SCH ₃ | Cl | (CDCl ₃) δ 1.84 (3H, s), 2.48 (3H, s), 2.88 (2H, d of d, J=7,7), 3.22 (1H, m), 3.40-3.66 (5H, m), 3.79 (1H, d, J=7), 6.88-7.14 (4H, m), 7.40 (2H, s). |
| 10 | Racemate | CH ₃ | CH ₃ | SCH ₃ | Cl | (CDCl ₃) δ 1.96 (3H, s), 2.46 (3H, s), 2.80 (1H, ab quartet, J=7.2), 2.82 (1H, ab quartet, J=7,20), 3.6 (1H, m), 3.32 (3H, s), 3.34-3.74 (6H, m), 6.88-7.10 (4H, m), 7.40 (2H, s). |
| 15 | Enantiomer | H | CH ₃ | SCH ₃ | Cl | (CDCl ₃) δ 1.80 (3H, s), 2.48 (3H, s), 2.88 (2H, d of d, J=7.7), 3.20 (1H, m), 3.40-3.66 (5H, m), 3.79 (1H, d, J=7), 6.88-7.14 (4H, m), 7.40 (2H, s). |
| 20 | Enantiomer | CH ₃ | CH ₃ | SCH ₃ | Cl | (CDCl ₃) δ 1.96 (3H, s), 2.46 (3H, s), 2.80 (1H, ab quartet, J=7.20), 2.82 (1H, ab quartet, J=7.20) 3.16 (1H, m), 3.32 (3H, s), 3.34-3.74, (6H, m), 6.88-7.10 (4H, m), 7.40 (2H, s). |
| 25 | Racemate | H | CH ₃ | SCH ₃ | CF ₃ | (CDCl ₃) δ 2.06 (3H, s), 2.24 (3H,s), 2.70 (1H, ab quartet, J=7, 30), 2.72 (1H, ab quartet, J=7,30), 3.20 (1H, m), 3.50-3.80 (6H, m), 6.88-7.12 (4H, m), 7.65 (2H, s). |
| 30 | Racemate | CH ₃ | CH ₃ | SCH ₃ | CF ₃ | (CDCl ₃) δ 2.12 (3H, s), 2.32 (3H, s), 2.78 (1H, ab quartet, J=7, 16), 2.80 (1H, ab quartet, J=7, 16), 3.18 (1H, m), 3.30 (3H, s), 3.50-3.90 (6H, m), 6.92-7.16 (4H, m), 7.64 (2H, s). |
| 35 | | | | | | |
| 40 | | | | | | |

-25-

| | | | | | | |
|----------|------------|-----------------|----|----|----|---|
| 5 | Racemate | H | Et | Et | Cl | (CDCl ₃) δ 0.84 (3H, t, J=7), 1.22 (3H, t, J=7), 2.28 (2H, q, J=7), 2.60 (2H, q, J=7), 2.56 (1H, d of d, J=7,15), 3.26 (1H, m), 3.50-3.86 (6H, m), 6.96-7.08 (4H, m), 7.42 (2H, s). |
| 10 15 | Racemate | CH ₃ | Et | Et | Cl | (CDCl ₃) δ 0.92 (3H, t, J=7), 1.20 (3H, t, J=7), 2.38 (2H, q, J=7), 2.66 (2H, q, J=7), 2.80 (1H, ab quartet, J=7, 40), 2.82 (1H, ab quartet, J=7, 40), 3.16 (1H, m), 3.34 (3H, s), 3.35-3.74 (6H, m), 6.92-7.10 (4H, m), 7.40 (2H, s). |
| 20 | Enantiomer | H | Et | Et | Cl | (CDCl ₃) δ 0.86 (3H, t, J=7), 1.20 (3H, t, J=7), 2.26 (2H, q, J=7), 2.58 (2H, q, J=7), 2.54 (1H, d of d, J=7, 15), 2.95 (1H, d of d, J=7, 15), 3.24 (1H, m), 3.48-3.84 (6H, m), 6.90-7.08 (4H, m), 7.40 (2H, s). |

-26-


EXAMPLE 8

The following compounds were prepared according to Examples 3 and 5.

5

10

15



20

25

30

35

| R | R ₁ | R ₂ | X | ¹ H-NMR |
|-----------------|-----------------|------------------|-----------------|--|
| CH ₃ | CH ₃ | SCH ₃ | Cl | (CDCl ₃) δ 1.48 (3H, s), 2.46 (3H, s), 3.92 (3H, s), 4.14 (2H, s), 7.18-7.38 (3H, m), 7.32 (2H, s), 7.68-7.88 (3H, m). |
| CH ₃ | Et | Et | CF ₃ | (CDCl ₃) δ 0.60 (3H, t, J=7), 1.04 (3H, t, J=7), 2.08 (2H, q, J=7), 2.46 (2H, q, J=7), 3.90 (3H, s), 4.26 (2H, s), 7.16-7.34 (3H, m), 7.58 (2H, s), 7.70-7.84 (3H, m). |
| H | CH ₃ | CH ₃ | Cl | (CDCl ₃) δ 1.80 (3H, s), 2.10 (3H, s), 4.20 (2H, s), 6.98 (1H, d, J=7), 7.26 (1H, t, J=7), 7.36 (2H, s), 7.37 (1H, t, J=7), 7.55 (1H, d, J=7), 7.72 (1H, d, J=7), 7.78 (1H, d, J=7). |
| CH ₃ | CH ₃ | CH ₃ | Cl | (CDCl ₃) δ 1.75 (3H, s), 2.06 (3H, s), 3.94 (3H, s), 4.23 (2H, s), 7.21-7.40 (3H, m), 7.40 (2H, s), 7.71-7.86 (3H, m). |

-27-

| | | | | | |
|---|-----------------|----|----|-----------------|---|
| 5 | CH ₃ | Et | Et | CF ₃ | (CDCl ₃) δ 0.6 (3H, t, J=7), 2.06 (3H, t, J=7), 2.08 (2H, q, J=7), 2.46 (2H, q, J=7), 3.90 (3H, s), 4.24 (2H, s), 7.18-7.36 (2H, m), 7.60 (2H, s), 7.71 (2H, d, J=8), 7.81 (2H, d, J=8). |
|---|-----------------|----|----|-----------------|---|

Example 9A. 3,5-Diethyl-1-(2,4,6-trimethylphenyl)pyrazole.

A solution of 7.46 g (0.04 mol) of 2,4,6-trimethylphenylhydrazine hydrochloride, 5.12 g (0.40 mol) of 3,5-heptanedione and 4.18 mL (0.60 mol) of triethylamine in 100 mL of absolute ethanol was refluxed overnight. The solvent was evaporated from the cooled reaction mixture and the residues were partitioned between water and ethyl acetate. The organic extracts were dried with brine and magnesium sulfate, and the solvent was evaporated to give the desired product in 95% yield. This compound was used in the subsequent reaction without further purification ¹H-NMR (CDCl₃): .11 (3H, t, J=7), 1.24 (3H, t, J=7), 1.90 (6H, s), 2.22 (2H, q, J=7), 2.28 (3H, s), 2.65 (2H, q, J=7), 5.96 (1H, s), 6.86 (2H, s).

B. 4-Bromo-3,5-diethyl-1-(2,4,6-trimethylphenyl)pyrazole.

A solution of 6.4 g (0.04 mol) of bromine in 20 mL of glacial acetic acid was added dropwise to a stirred solution of 9.00 g (37 mmol) of 3,5-diethyl-1-(2,4,6-trimethylphenyl)pyrazole in 100 mL of glacial acetic acid. After 1 hour at room temperature, the acetic acid was evaporated under reduced pressure and the residues were dissolved in ethyl acetate. This solution was washed with saturated sodium bicarbonate to remove residual acetic acid, dried with brine and magnesium sulfate, and was concentrated on the rotovap. The product was a tan solid (10.26 g, 25 purification. ¹H-NMR(CDCl₃): 0.92 (3H, t, J=7), 1.15 (3H, t, J=7), 1.86 (6H, s), 2.24 (3H, s), 2.32 (2H, q, J=7), 2.60 (2H, q, J=7), 6.82 (2H, s).

C. 3,5-Diethyl-1-(2,4,6-trimethylphenyl)pyrazole-4-methanol.

A solution of 1.0 g (3.1 mmol) of 4-bromo-3,5-diethyl-1-(2,4,6-trimethylphenyl)pyrazole in 10 mL of anhydrous ether in a flame-dried 3-neck round bottom flask under dry nitrogen with 3.85 mL of 1.7 M t-butyllithium in pentane. After 1 hour, the reaction mixture was treated with 0.355 mL of ethyl chloroformate and was then allowed to warm to room temperature. The reaction mixture was quenched with

-28-

water and then ethyl acetate was added. The aqueous layer was extracted with ethyl acetate again and the organic extracts were combined and dried with brine and magnesium sulfate and then the solvent was removed on the rotovap. This product, 3,5-diethyl-4-ethoxycarbonyl-1-(2,4,6-trimethylphenyl)pyrazole, was determined to be 59% pure by gas chromatographic (GC) analysis.

This material, approximately 3.1 mmol, was dissolved in 10 mL of ether and cooled under dry nitrogen to 0 °C. Then 7 mL (10 mmol) of 1.5M diisobutylaluminum hydride in toluene was added over about 10 minutes. The reaction mixture was stirred at 0 °C until no starting material was observed by GC and was then quenched with water. The product was extracted into ethyl acetate, dried with brine and magnesium sulfate, and concentrated. The residues were flash chromatographed on silica gel using 4:1 and 1:1 hexane/ethyl acetate as eluent to give the desired product as an oil in the amount of 0.565 g (69% yield for the two reactions). ¹H-NMR (CDCl₃): 0.94 (3H, t, J=7), 1.23 (3H, t, J=7), 1.88 (6H, s), 2.26 (3H, s), 2.35 (2H, t, J=7), 2.66 (2H, q, J=7), 4.50 (2H, s), 6.82 (2H, s).

D. {2-[3,5-Diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol.

To a solution of 272 mg (1.0 mmol) of 3,5-diethyl-1-(2,4,6-trimethylphenyl)pyrazole-4-methanol in 5 mL of methylene chloride cooled to 0 °C under dry nitrogen in a 25 mL 3-neck flask, was added 0.2 mL (2.5 mmol) of triethylamine and 0.092 mL (2.0 mmol) of methanesulfonyl chloride. This mixture was stirred for 15 minutes at 0 °C and then 0.648 g (4.0 mmol) of (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline in 1 mL of 50:50 dimethylformamide acetonitrile was added. The reaction mixture was heated at reflux overnight whereupon no starting material was seen by TLC. The cooled reaction mixture was diluted with water and the product was extracted with ethyl acetate. After drying (brine wash, magnesium sulfate) and evaporation, the crude product was chromatographed on silica gel, eluting with 10:1 and 5:1 hexane/ethyl acetate to give 184 mg (44%) of the desired product. ¹H-NMR (CDCl₃): 0.80 (3H, t, J=7), 1.18 (3H, t, J=7), 1.92 (6H, s), 2.21 (2H, q, J=7), 2.28 (3H, s), 2.55 (2H, q, J=7), 2.97 (2H, d of d, J=7), 3.25 (1H, m), 3.50 - 3.66 (5H, m), 3.80 (2H, d, J=12), 6.82 - 7.16 (6H, m).

-29-

E. 2-[3,5-Diethyl,1,(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline.

A solution of 150 mg (0.36 mmol) of {2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol in 5 mL of THF was stirred under dry nitrogen as 11 mg (0.43 mmol) of oil-free sodium hydride was added. The reaction mixture was stirred for 15 minutes and then 0.044 mL (0.72 mmol) of methyl iodide was added. The reaction mixture was stirred overnight and then diluted with water. The product was extracted into ethyl acetate and the organic extracts were dried with brine and magnesium sulfate, and evaporated. The product was isolated pure by chromatography on silica gel using 10:1 and 5:1 hexane/ethyl acetate as eluent to give 84 mg (52%) of a golden oil. ¹H-NMR (CDCl₃): 0.86 (3H, t, J=7), 1.20 (3H, t, J=7), 1.92 (6H, s), 2.28 (3H, s), 2.32 (2H, q, J=7), 2.63 (2H, q, J=7), 2.83 (2H, d of ABq), 3.17 (1H, m), 3.33 (3H, s), 3.34 - 3.38 (1H, m), 3.54 - 3.76 (5H, m), 6.83 - 7.16 (6H, m).

The following examples illustrate the preparation of intermediates.

Preparation 1

Racemic (1,2,3,4-Tetrahydro-Isoquinolin-3-yl)-methanol [also referred to as (±)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline]

To a well stirred, ice-bath-chilled slurry of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (75 g, 0.351 mol, Aldrich Chemical Co.) in anhydrous methanol (600 ml), sodium methoxide (37.92 g, 0.702 mol) was added in small solid portions over a 10 minute period. After 30 minutes of brisk stirring, the methanol was removed and the colorless residue was dried in vacuo overnight. The entire sample was stirred in anhydrous tetrahydrofuran causing the organic portion to dissolve completely. A 1.0 M solution of lithium aluminum hydride in tetrahydrofuran (351 ml, 0.351 mol) was added in a rapid stream to the well-stirred mixture over a 20 minute period (mild exotherm). The reaction mixture was then vigorously refluxed for 2 hours. At 5°C, the reaction was quenched by cautious addition of 15% aqueous sodium hydroxide. The mixture was filtered, and the filtrate was concentrated in vacuo to a yellow solid. The entire sample was then dissolved in methylene chloride (400 ml) and filtered to remove residual inorganic salts. Solvent removal in vacuo afforded the title compound as an orange solid (47.01 g, 70% yield). TLC R_f (silica gel plates, u.v.

-30-

detection, methanol/methylene chloride=5:95 in volume): 0.46; ^{13}C NMR(CDCl_3): 135.4, 134.1, 129.3, 126.3, 126.1, 125.9, 65.4, 55.0, 47.8, 30.9.

Preparation 2

Dextrorotatory enantiomer of (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol [also referred to as (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline]

To a solution of (\pm)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (Preparation 1; 47.01 g, 0.288 mol) in isopropyl alcohol (159 ml), a solution of (S)-(+)-mandelic acid (43.81 g, 0.288 mol) in isopropyl alcohol (159 ml) was added. The resulting solution was allowed to stand at ambient temperature for 48 hours, during which time a heavy orange crystalline mass formed. The isolated crystalline solid (13.06 g) was dissolved in hot isopropyl alcohol (63 ml). After standing for 1 hour at ambient temperature, the newly-formed crystalline solid was isolated by filtration (8.2 g, m.p. 138°C). The recrystallization procedure was repeated twice more, using 63 ml and 60 ml volumes of isopropyl alcohol to afford 7.08 g and 6.76 g of crystalline material, respectively. (In each case, the crystallization was allowed to proceed for 2 hours at ambient temperature prior to filtration.) A $138\text{--}139^\circ\text{C}$ m.p. was observed after the final crystallization. The entire sample was dissolved in methylene chloride water (300 ml and 100 ml, respectively) with the pH adjusted to 9.5 (potassium carbonate). The phases were separated, and the aqueous portion was extracted with three 50 ml portions of fresh methylene chloride. The combined organic extracts were dried (anhydrous sodium sulfate) and concentrated in vacuo to afford the optically resolved title compound as a colorless amorphous solid (2.02 g, 8.6% yield). $[\alpha]^{20}_{\text{D}} + 103^\circ$ ($c=1.83$, CH_2Cl_2); ^{13}C NMR (CDCl_3): Identical to that of the racemic compound prepared in Preparation 1.

Preparation 3

Levorotatory enantiomer of (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol [also referred to as (-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline]

Substituting (R)-(-)-mandelic acid for (S)-(+)-mandelic acid in the Preparation 2 procedure (and utilizing 17.9 g of the alcohol-amine prepared in Preparation 1), the levorotary title compound (0.65 g, 7.3% yield) was obtained as a colorless amorphous solid. $[\alpha]^{20}_{\text{D}} - 100.4^\circ$ (CH_2Cl_2 , $c=1.43$; ^1H NMR and ^{13}C NMR (CDCl_3): Identical in all respects to those observed for the racemic (Preparation 1) and dextrorotatory (Preparation 2) products.

-31-

Preparation 4Methyl 3,5-diethyl-1-(2,4,6-trichlorophenyl)pyrazole-4-carboxylate


A mixture of 11.0 g (60.0 mmol) of methyl 2-propionyl-3-ketopentanoate and 11.26 g (65.0 mmol) of 2,4,6-trichlorophenylhydrazine in 50 mL of ethanol was refluxed under nitrogen until disappearance of starting material was noted. The solvent was removed in vacuo and the residues were partitioned between ethyl acetate and dilute hydrogen chloride. The organic layer was dried and evaporated to give the product as an off-white solid which was used for subsequent reactions without further purification.

¹H-NMR: (CDCl₃) δ 1.02 (3H, t, J=7), 1.21 (3H, t, J=7), 2.62 (2H, q, J=7), 2.86 (2H, q, J=7), 3.82 (3H, s), 7.42 (2H, s).

-32-

CLAIMS

1. A compound of the formula



- 10 and the pharmaceutically acceptable acid addition salts thereof,
wherein

A is CH₂;

- R₁ is hydrogen; linear or branched C₁-C₆ alkyl; C₃-C₆ alkyl containing one or two non-adjacent double bonds; hydroxy; O(C₁-C₆ alkyl); SH; S(C₁-C₆ alkyl); or C₃-C₆ cycloalkyl; morpholinyl, piperidinyl or aryl which aryl may be substituted by one to three
15 of fluoro, chloro, bromo, hydroxy, O(C₁-C₆ alkyl), SH, S(C₁-C₆ alkyl), amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, or one of iodo, nitro or cyano, said aryl being selected from the group consisting of phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl,
20 benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, or thiazolidinyl;

- R₃ is linear C₁-C₆ alkyl, branched C₃-C₆ alkyl, C₃-C₆ alkenyl wherein the double bond is not adjacent to X₁ when X₁ is a heteroatom, C₃-C₇ cycloalkyl(CH₂)_n wherein n is 0 to 4, or (CH₂)_qQ₁R₁₈ wherein q is 0, 1 or 2, Q₁ is O, S, NH, N(C₁-C₆ alkyl), or a
25 covalent bond when X₁ is not a covalent bond, and R₁₈ is hydrogen, linear C₁-C₆ alkyl, branched C₃-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ cycloalkyl or C₃-C₆ cycloalkyl-(CH₂) with the proviso that when q is 1, then X₁ and Q₁ cannot both be a heteroatom;

X₁ is a covalent bond, CH₂, O, S, or NR, wherein R is hydrogen, linear C₁-C₆ alkyl or branched C₃-C₆ alkyl;

- 30 Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl,

-33-


each of which may be substituted by one to three of any one of fluoro, chloro, bromo, or methyl, or one of trifluoromethyl; with the proviso that Y is not unsubstituted phenyl; and

Z is

5

(a)

10



wherein the B ring is phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, thienyl, or indolyl, each of which may be substituted by methyl, methoxy, trifluoromethyl, fluoro, chloro, bromo or iodo; or a saturated 5- or 6-membered carbocyclic ring or a partially unsaturated ring having one or two double bonds;

20 R_4 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, hydroxy, fluoro, chloro, bromo, iodo or trifluoromethyl;

R_5 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, or $(CH_2)_o$ - X_2 -(CH_2) r - Q_2 - R_6 ;

X_2 and Q_2 are each independently O, S, NH, N(C_1 - C_6 alkyl), or one of X_2 and Q_2 may be a covalent bond;

25 R_6 is hydrogen, linear C_1 - C_6 alkyl, branched C_3 - C_8 alkyl, or C_3 - C_8 alkenyl;

m is 0 or 1;

o is 1 or 2;


p is 1 or 2; and

r is 0, 1 or 2.

30

-34-

(b)




5

wherein R_4 and R_5 are as defined above, and t and u are each independently 1 or 2;

(c) $-NR_7R_8$ wherein R_7 and R_8 are each independently hydrogen, C_1 - C_6 linear alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, $(CH_2)_vCH_2OH$, $(CH_2)_vNR_9R_{10}$, wherein v is 0 to 3, and R_9 and R_{10} are each independently hydrogen, or linear C_1 - C_6 alkyl; (C_3 - C_{12} cycloalkyl) $(CH_2)_n$, (C_6 - C_{10} bicycloalkyl) $(CH_2)_n$, benzofused C_3 - C_6 cycloalkyl, C_1 - C_6 hydroxyalkyl, phenyl $(CH_2)_n$, each of which may be substituted by one or two of hydroxy, fluoro, chloro, bromo, C_1 - C_5 alkyl, or C_1 - C_5 alkoxy; or R_7 and R_8 may be taken together with the nitrogen to form a saturated or partially unsaturated 5- to 7-membered ring which may contain one of O, S, NH or $N(C_1$ - C_6 alkyl) and which may be substituted by C_1 - C_6 alkyl, hydroxy or phenyl wherein any double bond(s) are not adjacent to any heteroatoms; and n is 0 to 4;

15

(d)



20

25


wherein B , W , R_4 and R_5 are as defined above, w , x , y and z are each independently 1 or 2, and W is $(CH_2)_q$ wherein q is as defined above, $N(C_1$ - C_6 alkyl), or oxygen;

30

-35-


(e)

5

10 wherein B, R_4 , m and p are as defined above;

(f)

15

wherein B and R_4 are as defined above;

20

(g) $O(CH_2)_v R_{11}$


wherein v is 0 to 3 and R_{11} is linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, or thienyl, each of which may be substituted by one or two of any one of fluoro, chloro, bromo, methyl, or trifluoromethyl;

30

-36-

(h)


5



wherein A is defined above and is linked to position 1 or 2 while R_{14} is attached to position 2 or 1, respectively; F, G, H, I, J and K are independently C or N, provided that not more than three of H, I, J and K are N with not more than two adjacent nitrogens; R_{12} and R_{13} each independently are hydrogen, linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, thiol, C_1 - C_{12} alkoxy, C_1 - C_{12} thioalkanyl, or C_3 - C_{12} alkenoxy or C_3 - C_{12} thioalkenyl wherein the double bond is not adjacent to the oxygen; and R_{14} is hydroxy, C_1 - C_{12} alkoxy, C_3 - C_{12} alkenoxy wherein the double bond is not adjacent to the oxygen, or $-X_2-(CH_2)_r-Q_2R_6$ wherein X_2 , r , Q_2 and R_6 are as defined above in paragraph (a) except that Q_2 is not sulfur, or R_{14} is $NR_{15}R_{16}$ wherein R_{15} and R_{16} are each independently hydrogen, linear C_1 - C_8 alkyl, branched C_3 - C_8 alkyl, C_3 - C_8 alkenyl wherein the double bond is not adjacent to the nitrogen, or C_3 - C_7 cycloalkyl- $(CH_2)_n$ wherein n is as defined above, or R_{15} and R_{16} together with the nitrogen form a saturated five or six membered ring optionally condensed with benzo; or

(i)

25




wherein D, E, F and G are independently C or N, provided that not more than two of D, E, F and G are N, R_{12} and R_{14} are as defined in paragraph (h), A, defined above, is linked to a carbon in formula VIII, and R_{14} is linked to the carbon located adjacent to the carbon to which A is linked.

30

-37-

2. A compound according to claim 1 wherein Y is 2,4,6-tri-substituted phenyl.
3. A compound according to claim 1 wherein Y is 2,4,6-trichlorophenyl, 2,6-dichloro-4-trifluoromethylphenyl, 2,6-dibromo-4-fluorophenyl, 2,6-dimethyl-4-bromophenyl, or 2,4,6-trimethylphenyl.
4. A compound according to claim 1,2 or 3 wherein X_1R_3 is ethyl or methylthio.
5. A compound according to any one of claims 1 to 4 wherein R_1 is (C_1-C_6) alkyl.
6. A compound according to any one of claims 1 to 5 wherein Z is NR_7R_8 wherein R_7 is phenyl or phenyl substituted by one of fluoro, chloro, trifluoromethyl, nitro, methyl or methoxy.
7. A compound according to claim 6 wherein R_8 is $CH_2CH_2CH_2OH$, CH_2CH_2OH , or methyl.
8. A compound according to any one of claims 1 to 5 wherein Z is 1,2,3,4-tetrahydroisoquinolin-2-yl substituted by R_5 which is $(CH_2)_o-X_2-(CH_2)_r-Q_2-R_6$.
9. A compound according to claim 8 wherein R_5 is $(CH_2)_kOH$ wherein k is 1 to 4, or $CH_2OCH_2CH_2OR_6$.
10. A compound according to any one of claims 1 to 5 wherein Z is 1, 2, 3, 4-tetrahydroisoquinolin-2-yl, wherein R_5 is substituted at position 3, and the absolute configuration at the 3-position is S or R or R,S.
11. A compound according to any one of claims 1 to 5 wherein Z is of the formula

25



- with the absolute configuration at position 3 determined by its derivation from (+)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline, wherein R_{19} is methyl, ethyl, isopropyl, cyclopropylmethylene, or 2-hydroxyethyl.


12. A compound according to claim 1 wherein Z is as defined in (h).

-38-

13. A compound according to claim 13 wherein A is linked to position 1, R_{14} is at position 2 and is $X_2 - (CH_2)_2 Q_2 R_6$.

14. A compound according to claim 14 wherein F, G, H, I, and J, are each carbon, K is carbon or nitrogen, and R_{14} is 2-methoxy, 2-ethoxy, 2-isopropoxy, or 2-cyclopropylmethoxy.


15. A compound according to any one of claims 1 to 5 wherein Z is



wherein K is C or N and R_{20} is methyl, ethyl, isopropyl, cyclopropylmethylene, methoxyethylene or hydroxyethylene.

16. A compound according to claim 1 wherein Z is as defined in (a), B is phenyl, p and m are each 1, and R_5 is CH_2OCH_3 or $CH_2OCH_2CH_2OH$.

17. A compound according to any one of claims 1 to 5 wherein Z is



wherein B is phenyl, m is 0, and p is 1.


18. A compound according to claim 1 which is 3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; (3R)-3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; 3-methoxymethyl-2-[5-methyl-3-methylsulfanyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinoline; {2-[5-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}methanol; {2-[5-methyl-3-methylsulfanyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-1H-

pyrazol-4-ylmethyl]-1,2,3,4-tetrahydroisoquinolin-3-yl)methanol; 2-{1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-naphthalene-2-yloxy}-ethanol; 2-{8-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-quinolin-7-yloxy}-ethanol; 2-[3,5-diethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline; 1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-4-(2-methoxynaphthalen-1-ylmethyl)-1H-pyrazole; 2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline; 2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-3-methoxymethyl-1,2,3,4-tetrahydroisoquinoline; 2-[1-(2,6-dichloro-4-trifluoromethylphenyl)-3,5-diethyl-1H-pyrazol-4-ylmethyl]-3-ethoxymethyl-1,2,3,4-tetrahydroisoquinoline, or 2-[3,5-diethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazol-4-ylmethyl]-3-ethoxymethyl-1,2,3,4-tetrahydroisoquinoline.

19. A composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) stress and anxiety related disorders including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises a compound of the formula I as defined in claim 1 in an amount effective in the treatment of said illnesses, and a pharmaceutically acceptable carrier.

20. A method for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) stress and anxiety related disorders including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises administering to a subject in need of such treatment a compound of formula I as defined in claim 1.

21. A compound of the formula



-40-

wherein A is CH₂, R₃ is linear C₁-C₆ alkyl, branched C₃-C₈ alkyl, C₃-C₈ alkenyl wherein the double bond is not adjacent to the N or X₁ when X₁ is oxygen or sulfur, C₃-C₇ cycloalkyl (CH₂)_n wherein n is 0, 1, 2, 3 or 4; or (CH₂)_qQ₁R₆ wherein q is 0, 1 or 2, Q₁ is O, S, NH, N(C₁-C₆ alkyl) or a covalent bond, and R₆ is hydrogen, linear C₁-C₆ alkyl, 5 branched C₃-C₈ alkyl, C₃-C₈ alkenyl, C₃-C₈ cycloalkyl, or C₃-C₈ cycloalkyl (CH₂)_n wherein n is 0 to 4, with the proviso that when q is 1, then X₁ and Q₁ can not both be a heteroatom;

X₁ is a covalent bond, CH₂NR, wherein R is hydrogen or linear C₁-C₆ alkyl, O, or S;

10 Y is phenyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, thiazolyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, isoxazolyl, benzisoxazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, benzoxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, or piperidinyl, each of which may be substituted by one to three of any one of fluoro, chloro, bromo, 15 or methyl, or one of trifluoromethyl, provided that Y is not unsubstituted phenyl, and

L is chloro, bromo, iodo, hydroxy, O(C=O)(C₁-C₆ alkyl), OSO₂(C₁-C₆ alkyl), OSO₂aryl wherein said aryl is phenyl which may be substituted by one to three of fluoro, chloro, bromo, hydroxy, O(C₁-C₆ alkyl), SH, S(C₁-C₆ alkyl), amino, NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)₂, or one of iodo, nitro or cyano.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/09170

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D401/06 C07D231/12 C07D231/18 A61K31/415 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | US,A,5 063 245 (M. E. ABREU ET AL.) 5 November 1991 cited in the application see claim 1 ----- | 1,19 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

6 January 1994

Date of mailing of the international search report

14. 01. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/09170

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 20 is directed to a method of treatment of (diagnostic practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 93/09170

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| US-A-5063245 | 05-11-91 | NONE | |